RxDoctor Payments Data

David Dimarco

Optometrist · Wexford, PANPI 1912104811

Payments from drug & device makers

$3,401in general payments, 2019–2025

Across 138 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$647
  • Johnson & Johnson Vision Care, Inc.$445
  • AbbVie$399
  • Tarsus Pharmaceuticals, Inc.$371
  • Sun Pharmaceutical Industries Inc.$350
  • Oyster Point Pharma, Inc.$253
  • plus $935 from 17 others

What the payments were for

  • Food & beverage$3,401100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,401 in reported general payments places this provider in the 85th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,022
Medicare patients
428
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$25,593
Cyclosporine31$21,012
LumiganBimatoprost31$11,415
VyzultaLatanoprostene Bunod13$7,455
Latanoprost237$2,589
Tobramycin-DexamethasoneTobramycin/Dexamethasone66$2,285
Fluorometholone25$1,623
Brimonidine Tartrate22$1,443
Prednisolone Acetate28$865
Timolol Maleate77$740
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$451
MoxifloxacinMoxifloxacin Hcl20$253
Dorzolamide Hcl12$209
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$159
ErythromycinErythromycin Base11$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$399$37,00752 claims
Bausch & Lomb Americas Inc.Vyzulta$647$7,45513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Wexford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →